Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
![]() |
Yoo, Chang-Hoon
(Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
Kim, Shin (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Sohn, Byeong-Seok (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Kim, Jeong-Eun (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) Yoon, Dok-Hyun (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Huh, Joo-Ryung (Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine) Lee, Dae-Ho (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Kim, Sang-We (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Lee, Jung-Shin (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) Suh, Cheol-Won (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine) |
1 | Ngo L, Hee SW, Lim LC, et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008;49:462-469. DOI ScienceOn |
2 | Ko OB, Jang G, Kim S, Huh J, Suh C. Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement. Korean J Intern Med 2008;23:182-190. DOI ScienceOn |
3 | Park YH, Lee JJ, Ryu MH, et al. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol 2006;85:257-262. DOI ScienceOn |
4 | Wilson KS, Sehn LH, Berry B, et al. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:1102-1109. DOI ScienceOn |
5 | Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861. DOI ScienceOn |
6 | Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008;19:1921-1926. DOI ScienceOn |
7 | Kim HT, Im YH, Suh CI, et al. Malignant lymphomas in Korea. J Korean Cancer Assoc 1992;24:92-101. |
8 | Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244. |
9 | Ho FC, Todd D, Loke SL, Ng RP, Khoo RK. Clinico-pathological features of malignant lymphomas in 294 Hong Kong Chinese patients, retrospective study covering an eight-year period. Int J Cancer 1984;34:143-148. DOI |
10 | Hahn JS, Lee S, Chong SY, Min YH, Ko YW. Eight-year experience of malignant lymphoma: survival and prognostic factors. Yonsei Med J 1997;38:270-284. |
11 | Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-391. DOI ScienceOn |
12 | Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279-4284. DOI ScienceOn |
13 | Hermans J, Krol AD, van Groningen K, et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 1995;86:1460-1463. |
14 | Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features: Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998;83:806-812. DOI ScienceOn |
15 | Greiner TC, Medeiros LJ, Jaffe ES. Non-Hodgkin's lymphoma. Cancer 1995;75(1 Suppl):370-380. |
16 | Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002-1006. DOI ScienceOn |
17 | Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995-1007. DOI ScienceOn |
18 | Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-4126. DOI ScienceOn |
![]() |